How are antibodies involved in the protective mechanism of susceptible mice infected with T. cruzi?

Brazilian Journal of Medical and Biological Research

Volumn 33, Issue 3, 2000, Pages 253-258

  Umekita, L F ^a   Mota, I ^a  

^a INSTITUTO BUTANTAN   (Brazil)

Author keywords

Acute phase; Chronic mouse antibodies; Clearance; Cytokines; Susceptible mice; Trypanosoma cruzi

Indexed keywords

CYTOKINE; PROTOZOON ANTIBODY;

ANIMAL; CHAGAS DISEASE; DISEASE PREDISPOSITION; IMMUNOLOGY; MOUSE; PHYSIOLOGY; REVIEW; TRYPANOSOMA CRUZI;

ANIMALS; ANTIBODIES, PROTOZOAN; CHAGAS DISEASE; CYTOKINES; DISEASE SUSCEPTIBILITY; MICE; TRYPANOSOMA CRUZI;

EID: 0034145460     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2000000300001     Document Type: Article

References (55)

1. Abrahamsohn IA & Coffman RL (1996). Trypanosoma cruzi: IL-10, TNF-α, IFN-γ and IL-12 regulate innate and acquired immunity to infection. Experimental Parasitology, 84: 231-244.
2. Reed SG, Grabstein KH, Pihl DL & Morrissey PJ (1990). Recombinant granulocyte-macrophage colony stimulating factor restores deficient immune responses in mice with chronic Trypanosoma cruzi infections. Journal of Immunology, 145: 1564-1570.
3. Silva JS, Vespa GNR, Cardoso MAG, Aliberti JCS & Cunha FQ (1995). Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infection and Immunity, 63: 4862-4867.
4. Christoph H, Kohler G, Muller U, Mossmann H, Schaub GA & Brombacher F (1998). Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruzi-infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Infection and Immunity, 66: 1208-1215.
5. Hunter CA, Slifer T & Araujo F (1996). Interleukin-12-mediated resistance to Trypanosoma cruzi is dependent on tumor necrosis factor alpha and IFN-γ. Infection and Immunity, 64: 2381-2386.
6. Kagi D, Ledermann B, Burk K, Zinkernagel RM & Hengartner H (1996). Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogens in vivo. Annual Review of Immunology, 14: 207-232.
7. Vespa GNR, Cunha FQ & Silva JS (1994). Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infection and Immunity, 62: 5177-5182.
8. Font EO, De Baetselier P, Heirman C, Thiclemans K, Lucas R & Vray B (1988). Effects of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha on Trypanosoma cruzi trypomastigotes. Infection and Immunity, 66: 2722-2727.
9. Lima ECS, Garcia I, Vicentelli MH, Vassalli P & Minoprio P (1997). Evidence for a protective role of tumor necrosis factor in the acute phase of Trypanosoma cruzi infection in mice. Infection and Immunity, 65: 457-465.
10. Nickell SP, Stryker GA & Arevalo C (1993). Isolation from Trypanosoma cruzi-infected mice of CD8+ MHC-restricted cytotoxic T cells that lyse parasite-infected target cells. Journal of Immunology, 150: 1446-1457.
11. Kumar S & Tarleton RL (1998). The relative contribution of antibody production and CD8+ T cell function to immune control of Trypanosoma cruzi. Parasite Immunology, 20: 207-216.
12. Tarleton RL, Koller BH, Latour A & Postan M (1992). Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature, 356: 338-340.
13. Silva JS, Twardzik D & Reed SG (1991). Regulaton of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor-β. Journal of Experimental Medicine, 174: 539-545.
14. Reed SG, Brownell CE, Russo DM, Silva JS, Grabstein KH & Morrissey PJ (1994). IL-10 mediates susceptibility to Trypanosoma cruzi infection. Journal of Immunology, 153: 3135-3140.
15. Gazzinelli RT, Oswald IP, James SL & Sher A (1991). IL-10 inhibits parasite killing and nitrogen oxide production by IFN-γ-activated macrophages. Journal of Immunology, 148: 1792-1796.
16. Martins GA, Cardoso MAG, Aliberti JCSA & Silva JS (1998). Nitric oxide-induced aooptotic cell death in the acute phase of Trypanosoma cruzi infection. Journal of Experimental Medicine, 175: 169-174.
17. Brener Z (1980). Immunity to Trypanosoma cruzi. Advances in Parasitology, 18: 247-292.
18. Tarleton RL (1997). Immunity to Trypanosoma cruzi. In: Haufmann SHE (Editor), Host Response to Intracellular Pathogens. Landes Company, Austin, TX, 227-247.
19. Brener Z & Krettli AU (1990). Immunology of Chagas disease. In: David J & Wyler WH (Editors), Modern Parasite Biology. Cellular, Immunological and Molecular Aspects. Freeman and Company, New York, 247-261.
20. Umekita LF, Takehara HA & Mota I (1988). Role of the antibody Fc in the immune clearance of Trypanosoma cruzi. Immunology Letters, 17: 85-89.
21. Martins MS, Hudson L, Krettli AU, Cançado JR & Brener Z (1985). Human and mouse sera recognize the same polypeptide associated with immunological resistance to Trypanosoma cruzi infection. Clinical and Experimental Immunology, 61: 343-350.
22. Norris KA, Harth G & So M (1989). Purification of a Trypanosoma cruzi membrane glycoprotein which elicits lytic antibodies. Infection and Immunity, 57: 2372-2377.
23. Umezawa ES, Stolf AM & Zingales B (1993). Trypanosoma cruzi: different surface antigens of trypomastigotes are target of lytic antibodies. Acta Tropica, 54: 41-53.
24. Norris KA, Bradt B, Cooper N & So M (1991). Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the complement regulatory protein, decay accelerating factor. Journal of Immunology, 147: 2240-2247.
25. Norris KA & Schrimph JE (1994). Biochemical analysis of the membrane and soluble forms of the complement regulatory protein of Trypanosoma cruzi. Infection and Immunity, 62: 236-243.
26. Mota I & Umekita LF (1989). The effect of C3 depletion on the clearance of Trypanosoma cruzi induced by IgG antibodies. Immunology Letters, 21: 223-226.
27. Umekita LF & Mota I (1990). Role of platelet in the in vivo removal of Trypanosoma cruzi from circulation. Brazilian Journal of Medical and Biological Research, 23: 593-596.
28. Joseph M, Auriault C, Capron A, Vorng H & Viens P (1983). A new function for platelets: IgE-dependent killing of Schistosomes. Nature, 303: 310-312.
29. Pancré V, Cesbron VY, Auriault C, Joseph M, Chandenier J & Capron A (1988). IgE-dependent killing of Brugia malayi microfilariae by human platelets and its modulation by T cell products. International Archives of Allergy and Applied Immunology, 85: 483-486.
30. Soper WD, Bartlett SP & Winn HJ (1982). Lysis of antibody-coated cells by platelets. Journal of Experimental Medicine, 156: 1210-1221.
31. Viens P, Dubois R & Kongshavn PAL (1983). Platelet activity in immune lysis of Trypanosoma musculi. International Journal for Parasitology, 13: 527-530.
32. Tanowitz HB, Burns GR, Sinha AK, Kahn NN, Morris SA, Factor SM, Hatcher VB, Bilezikian JP, Baum SG & Wittner M (1990). Enhanced platelet adherence and aggregation in Chagas' disease: a potential pathogenic mechanism for cardiomyopathy. American Journal of Tropical Medicine and Hygiene, 43: 274-281.
33. Umekita LF & Mota I (1989). In vitro lysis of sensitized Trypanosoma cruzi by platelets: role of C3b receptors. Parasite Immunology, 11: 561-566.
34. Umekita LF, Piazza RMF & Mota I (1994). Role of platelets and complement in the clearance of epimastigote forms of Trypanosoma cruzi. Brazilian Journal of Medical and Biological Research, 27: 2391-2399.
35. Umekita LF, Carneiro SM & Mota I (1998). One fate of epimastigote forms of Trypanosoma cruzi injected in mice. An ultrastructural study. Journal of Parasitology, 84: 1190-1195.
36. Norris KA (1998). Stable transfection of Trypanosoma cruzi epimastigotes with the trypomastigote-specific complement regulatory protein cDNA confers complement resistance. Infection and Immunity, 66: 2460-2465.
37. Franchin G, Pereira-Chioccola VL, Schenkman S & Rodrigues MM (1997). Passive transfer of a monoclonal antibody specific for a sialic acid-dependent epitope on the surface of Trypanosoma cruzi trypomastigotes reduces infection in mice. Infection and Immunity, 65: 2548-2554.
38. Krettli AU, Weiss CP & Nussenzweig RS (1979). Membrane-bound antibodies of bloodstream Trypanosoma cruzi in mice strain difference in susceptibility to complement mediated lysis. Clinical and Experimental Immunology, 37: 416-426.
39. De Gaspari EN, Stolf AMS, Umezawa ES, Zingales B & Abrahamsohn I (1994). Trypanosoma cruzi: studies on the reactivity of antibodies bound to the surface of blood forms at the early phase of infection. Acta Tropica, 56: 79-87.
40. Garcia IE, Lima MRI, Marinho CRF & Mosig JA (1997). Role of membrane bound IgM in Trypanosoma cruzi evasion from immune clearance. Journal of Parasitology, 83: 230-233.
41. Brodskyn CI, Moura AM, Takehara HA & Mota I (1988). Characterization of antibody isotype responsible for immune clearance in mice infected with Trypanosoma cruzi. Immunology Letters, 18: 255-258.
42. Umekita LF, Ramos DP, Barbaro KC & Mota I (1999). Biological activity of chronic phase antibodies eluted from sensitized Trypanosoma cruzi trypomastigotes. Immunology Letters, 70: 73-76.
43. Umekita LF, Ramos DP & Mota I (1997). Clearance-inducing antibodies are responsible for protection against the acute phase of Trypanosoma cruzi infection in mice. Brazilian Journal of Medical and Biological Research, 30: 1191-1197.
44. Umekita LF, Leite RA, Barbaro KC & Mota I (2000). Anti Trypanosoma cruzi antibodies in mice after revertion of chronic phase to the acute phase of infection induced by irradiation. Acta Tropica (in press).
45. 75Se-labelled Trypanosoma brucei in mice. II- Mechanisms in immune animals. Immunology, 40: 629-635.
46. Dempsey WL & Mansfield JM (1973). Lymphocyte function in experimental African trypanosomiasis. Role of antibody and the mononuclear phagocytic system in variant-specific immunity. Journal of Immunology, 130: 405-411.
47. 75Se-methionine labelled Trypanosoma cruzi blood trypomastigotes: opsonization by chronic infection serum facilitates killing in spleen and liver. Clinical and Experimental Immunology, 48: 754-757.
48. Gregory SH & Wing EJ (1998). Neutrophil-Kupffer-cell interaction in host defenses to systemic infections. Immunology Today, 19: 507-510.
49. Kongshavn PAL, Shaw K, Ghadirian E & Ulczak O (1990). Failure to demonstrate a major role for Kupffer cells and radiosensitive leukocytes in immunoglobulin-mediated elimination of Trypanosoma musculi. Infection and Immunity, 58: 1971-1978.
50. Umekita LF, Carneiro SM, Sesso A & Mota I (1999). One fate of bloodstream trypomastigote forms of Trypanosoma cruzi after immune clearance. An ultrastructural study. Journal of Parasitology, 85: 867-872.
51. Shaw KTY, Mawji Y, Stevenson MM & Kongshavn PAL (1991). Cells within the vascular system capable of mediating trypanocidal activity in vitro. Infection and Immunity, 59: 3143-3150.
52. Johnson PM, Trenchev P & Page Faulk W (1975). Immunological studies of human placentae. Binding of complexed immunoglobulin by stromal endothelial cells. Clinical and Experimental Immunology, 22: 133-138.
53. Ryan US, Schultz DR & Ryan JW (1981). Fc and C3b receptors on pulmonary endothelial cell: induction by injury. Science, 214: 557-558.
54. Palmer RM, Ferrige AG & Moncada S (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature, 327: 524-526.
55. Umekita LF, Lopes-Ferreira MV, Fontes-Piazza RM, Umezavva ES, Nascimento MS, Poliselli-Farsky SH & Mota I (2000). Alterations of the microcirculatory network during the clearance of epimastigote forms of Trypanosoma cruzi. An intravital microscopic study. Journal of Parasitology (in press).